Cemsidomide + Elranatamab for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and tolerability of combining cemsidomide and elranatamab for people with multiple myeloma that has returned or resisted past treatments. Researchers will first explore different doses to find a safe combination, then assess its effectiveness against the cancer. Ideal candidates for this trial have multiple myeloma, measurable disease, and have tried 1-4 other treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new treatment combination.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that cemsidomide, when combined with dexamethasone, yields promising results for treating multiple myeloma. Earlier studies reported a 40% to 53% success rate at higher doses, indicating some effectiveness, though the full impact remains under investigation.
Elranatamab has also been tested alone. In those studies, it produced strong and lasting improvements in patients. Serious side effects occurred in about 46.6% to 58.6% of patients, but these were considered manageable.
Early studies suggest that both treatments are generally well-tolerated, though some side effects may occur. These findings are crucial for researchers in determining the best doses to test further in this trial.12345Why are researchers excited about this trial's treatments?
Cemsidomide and Elranatamab are unique because they offer a new approach for treating multiple myeloma. While traditional treatments often include drugs like bortezomib, lenalidomide, or carfilzomib, which target the cancer cells directly or modulate the immune system, these investigational drugs work differently. Cemsidomide is a novel cereblon E3 ligase modulator (CELMoD), potentially offering a new mechanism to degrade proteins involved in the disease. Elranatamab is a bispecific antibody that targets BCMA (B-cell maturation antigen) on myeloma cells and engages T-cells to attack them, providing a fresh immune-based strategy. Researchers are excited because these drugs could offer enhanced effectiveness by combining these innovative mechanisms, potentially leading to better outcomes for patients.
What evidence suggests that cemsidomide and elranatamab could be effective for multiple myeloma?
Research has shown that cemsidomide, when combined with dexamethasone, yields promising results for treating multiple myeloma. Studies have found that 40% to 53% of patients responded positively to higher doses of this treatment, indicating cancer improvement. Elranatamab alone has also helped patients live longer without disease progression. In this trial, participants will receive a combination of cemsidomide and elranatamab, potentially harnessing the strengths of both treatments. This offers hope for those whose multiple myeloma has returned or not responded to other treatments. Early results suggest strong activation of T-cells, which play a crucial role in fighting cancer.12567
Are You a Good Fit for This Trial?
This trial is for people with multiple myeloma that has come back or hasn't responded to treatment. Participants should be able to take medication orally and receive subcutaneous injections. The full eligibility criteria are not provided, so interested individuals should inquire further.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Evaluation
Evaluation of different dose levels of cemsidomide in combination with elranatamab
Treatment
Cemsidomide taken orally for 14 days on/14 days off per cycle; Elranatamab administered by subcutaneous injection twice a month; Dexamethasone administered weekly until a confirmed response but no longer than 4 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cemsidomide
- Elranatamab
Trial Overview
The study tests the safety of a new drug combo: Cemsidomide (oral pill) and Elranatamab (injection), for relapsed/refractory multiple myeloma. It starts by finding a safe dose of Cemsidomide to use with Elranatamab, then expands to more patients at this dose.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
C4 Therapeutics, Inc.
Lead Sponsor
Citations
Updated Data From Phase 1 Trial of Cemsidomide in ...
Cemsidomide Phase 1 Data Has Demonstrated Class-leading Anti-myeloma ... Best Response: Multiple Myeloma – Cemsidomide 14/14 + Dex*. 33% (2). 8 ...
2.
c4therapeutics.gcs-web.com
c4therapeutics.gcs-web.com/news-releases/news-release-details/c4-therapeutics-announces-clinical-trial-collaboration-andC4 Therapeutics Announces Clinical Trial Collaboration and ...
Data generated from the cemsidomide Phase 1 trial in relapsed/refractory multiple myeloma demonstrate robust T-cell activation and cytokine ...
Comparison of outcomes with elranatamab and real world ...
In unadjusted analyses the elranatamab cohort had significant improvements in PFS (dRMST 6.95 months [4.08–9.61]) and OS (Hazard Ratio (HR) 0.66 ...
4.
ir.c4therapeutics.com
ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-third-quarter-2025-financial-results-andC4 Therapeutics Reports Third Quarter 2025 Financial ...
In the Phase 1 trial, cemsidomide in combination with dexamethasone achieved a 40% and 53% overall response rate at the two highest dose levels, 75 µg and 100 ...
5.
dailynews.ascopubs.org
dailynews.ascopubs.org/do/combination-elranatamab-daratumumab-lenalidomide-shows-promise-yielding-high-responseCombination Elranatamab, Daratumumab, Lenalidomide ...
The overall response rate was 97.3%, with 94.6% of patients having very good or partial responses and 27.0% having a complete response; the ...
6.
rarecancernews.com
rarecancernews.com/news/developers-partner-test-cemsidomide-plus-elrexfio-myeloma-trial/Developers partner to test cemsidomide plus Elrexfio for ...
C4 Therapeutics and Pfizer are partnering to test a cemsidomide and Elrexfio combination treatment for myeloma, with a trial next year.
Elranatamab in relapsed or refractory multiple myeloma
With biweekly dosing, grade 3–4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.